Print Share Email Send Email Your Name (required) ! Example: John Doe Email Address (required) ! Error: Please enter a valid sender email address. Example: firstname.lastname@example.org CC Me Recipient Email Address (required) ! Separate multiple email address with semi-colons (up to 5). Subject Subject for your email. Message (Maximum characters: 1,000) Error: Please enter your name Error: Please enter your email address Error: Please enter a valid recipient email address. Example:email@example.com Thank you! Your email has been sent to: The recipient(s) will receive an email message that includes a link to the selected article. Recipients may need to check their spam filters or confirm that the address is safe. Return to: Send Another Email An error has occurred sending your email(s). Please try again later or contact an administrator at OnlineCustomer_Service@email.mheducation.com. Return to: Twitter Facebook Linkedin Reddit Get Citation Citation AMA Citation Alexander SA, Castillo JG. Alexander S.A., Castillo J.G. Alexander, Steven A., and Javier G. Castillo. "Observational Study from the France-TAVI Registry Indicates that Balloon-Expandable Transcatheter Aortic Valves are Safer than Self-Expandable Valves." Hurst's the Heart Updates, 19 December 2019. McGraw-Hill, New York, NY, 2019. AccessCardiology. http://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=515001§ionid=234854721 MLA Citation Alexander SA, Castillo JG. Alexander S.A., Castillo J.G. Alexander, Steven A., and Javier G. Castillo.. "Observational Study from the France-TAVI Registry Indicates that Balloon-Expandable Transcatheter Aortic Valves are Safer than Self-Expandable Valves." Hurst's the Heart Updates Fuster V. Fuster V Fuster, Valentin. New York, NY: McGraw-Hill, 2019, http://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=515001§ionid=234854721. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Tools Clip Full Chapter Figures Only Tables Only Videos Only Supplementary Content Top Observational Study from the France-TAVI Registry Indicates that Balloon-Expandable Transcatheter Aortic Valves are Safer than Self-Expandable Valves by Steven A. Alexander, Javier G. Castillo Listen + +Update to Chapter 47: Aortic Valve Disease Study Summary + +In this study from the France-TAVI registry, balloon-expandable (BE) transcatheter aortic valves were compared with self-expandable (SE) valves for paravalvular regurgitation (PVR) and mortality. Between 2013 and 2015, the nationwide registry included 12,141 patients who received a BE valve or a SE valve for aortic stenosis. Using propensity scores (25 clinical, anatomical, and procedural variables) and the date of the procedure (within 3 months), patients treated with a BE valve (Edwards; n = 3,910) were matched 1:1 with patients treated with a SE valve (Medtronic; n = 3,910). The first co-primary outcome was the occurrence of moderate-to-severe PVR or in-hospital mortality. The second co-primary outcome was all-cause mortality at 2 years. +In matched propensity-score analysis, the incidence of the first co-primary outcome was higher with SE than with BE valves (19.8% vs 11.9%; RR 1.68; 95% CI 1.46–1.91; P <0.0001). Each component of the outcome was more frequent in patients who received a SE valve. During follow-up (median 20 months), all-cause mortality was higher for SE than for BE valves (2-year Kaplan–Meier estimate, 29.8% vs 26.6%; HR 1.17; 95% CI 1.06–1.29; P = 0.003). The impact of PVR on short-term mortality remains unclear. Although excess mortality was observed in the first few months after the procedure, the mortality risk persisted after adjustment for PVR, suggesting that PVR is acting as a marker rather than being the main driver of the mortality difference between the valve designs. Commentary + +Study Strengths: To date, this is the largest observational comparison of the effect of SE and BE valves on PVR and 2-year mortality. The prespecified falsification endpoints demonstrated no differences between valve types, suggesting adequate control of unmeasured confounders. Similar methodology has previously been highly predictive of the results of randomized studies. +Study Limitations: This is not a randomized trial and potential differences in unmeasured variables might remain. Specifically, extensive valve/root calcification and small femoral size were not measured and could be more frequent in patients receiving a SE than a BE valve, explaining all or part of the difference in mortality. Furthermore, severity of PVR and clinical events were site-reported and not centrally adjudicated, potentially resulting in heterogeneity in PVR grading and under-reporting of events. The newest SE valve (Evolut-Pro) was not available during the study period and, therefore, the results of this study may now have less relevance. +Next Steps/Clinical Perspective: This study from the FRANCE-TAVI registry suggests important differences in clinical outcomes relating to valve design. However, propensity-score matching cannot rule out residual confounders, and the most-recent valve technologies were not investigated. A contemporary randomized clinical trial powered to compare SE and BE valves would overcome these limitations but is unlikely to occur. Trial Reference + + + +Van Belle, E. et al. Balloon-expandable versus self-expanding transcatheter aortic valve eplacement: a propensity-matched comparison from the France-TAVI registry. Circulation doi:10.1161/CIRCULATIONAHA.119.043785AA (2019).